Mechanisms of neurological injury in COVID-19

Ajay Kumar Mishra
Saint Vincent Hospital

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/covid19

Part of the Infectious Disease Commons, Nervous System Diseases Commons, Neurology Commons, and the Virus Diseases Commons

Repository Citation
Retrieved from https://escholarship.umassmed.edu/covid19/41

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in COVID-19 Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Mechanisms of neurological injury in COVID-19

Ajay Kumar Mishra, MD, Amos Lal, Kamal Kant Sahu, MD, Anu Anna George, MD, Jennifer Sargent, DO

PII: S1878-8750(20)31060-3
DOI: https://doi.org/10.1016/j.wneu.2020.05.089
Reference: WNEU 15025

To appear in: World Neurosurgery

Received Date: 8 May 2020
Accepted Date: 9 May 2020


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Inc. All rights reserved.
Title page

Type of article: Letter to Editor

Title: Mechanisms of neurological injury in COVID-19

Ajay Kumar Mishra*MD, Amos Lal**, Kamal Kant Sahu*MD, Anu Anna George*MD, Jennifer Sargent***DO

Corresponding author,
Dr. Ajay Kumar Mishra, MD
Department of Internal Medicine
Saint Vincent Hospital
Worcester, Massachusetts
USA, 01608
Ajay.Mishra@stvincenthospital.com
Phone: 5083635000
Word count: 488
Number of Pages: 3

* Postgraduate in Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts
** Fellow in Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
*** Assistant Professor in Internal Medicine, University of Massachusetts Medical School, Saint Vincent Hospital, Worcester, Massachusetts
2. Dr. Amos Lal

Department of Pulmonology and Critical Care Medicine,
Mayo Clinic, Rochester
Minnesota, USA
Lal.Amos@mayo.edu

3. Dr. Kamal Kant Sahu, MD
Department of Internal Medicine
Saint Vincent Hospital
Worcester, Massachusetts
USA, 01608
kamalkant.sahu@stvincenthospital.com

4. Dr. Anu Anna George

Department of Internal Medicine
St Vincent Hospital
123 summer street, Worcester, MA
anugeorg@gmail.com

5. Jennifer Sargent, DO, FACP
Department of Internal Medicine,
Saint Vincent Hospital, and
University of Massachusetts Medical School
Worcester, Massachusetts
USA, 01608
CONFLICT OF INTEREST: Authors have no conflicts of interest to declare.

ETHICAL STATEMENT: The article doesn’t contain the participation of any human being and animal.

VERIFICATION: All authors have seen the manuscript and agree to the content and data. All the authors played a significant role in the paper.

Patient consent: Not applicable
We read with much interest the article “Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community” by Werner et al. published in your esteemed Journal. Authors have described the various neurological details of COVID-19 in detail.¹ We believe this topic is important and is continuously evolving. We have the following comments as an addition to the article.

Symptomatic patients with COVID-19 can present with mild, moderate, or severe illness. Across all studies, patients with severe illness have multi-organ involvement. Patients with severe disease are prone to develop acute respiratory distress syndrome (ARDS), acute cardiac injury, acute renal failure, acute liver dysfunction.² While several patterns of central nervous system involvement have been reported among these patients, diffuse CNS involvement has been reported to be higher.³

Multiple mechanisms could contribute to the initiation and progression of CNS injury in COVID-19 patients.

i] Cytokine storm, defined as dysfunctional, uncontrolled, continuous activation of inflammation has been consistently reported across all studies. This exaggerated inflammation has been postulated to contribute to ARDS, myocardial injury, renal failure, severity of illness, requirement of intensive care unit admission, requirement of mechanical ventilation, and mortality. This has been diagnosed with an elevated level of inflammatory markers including C-reactive protein, leukocytes, pro calcitonin, proBNP, ferritin, interleukins, and various other
inflammatory markers. While diffuse CNS involvement is noted to be higher among patients with severe illness, a temporal association between inflammatory markers and CNS dysfunction is not yet shown.4,5

ii] Autopsy studies on COVID-19 patients have been limited. Direct viral invasion has been reported in various organs including lung, liver, and heart. However, no reports have yet identified the virus, or viral particles in the brain.6

iii] hypoxia induced apoptosis and ischemia, presenting in most patients as multiorgan dysfunction.7

iv] prothrombotic state secondary to endothelial injury, thrombocytopenia, deranged coagulation parameters as evident from the raised D-dimer, fibrinogen, prothrombin time.6,8

v] embolic events secondary to myocardial dysfunction, with increased risk of arrhythmia. This has been supported by the presence of several raised cardiac markers including high-sensitivity troponins, and D-dimer.6,8,9

vi] among patients with severe illness multiple other contributors of central nervous system dysfunction requiring consideration are a) prolonged requirement of CNS depressing agents including benzodiazepines [Diazepam, Midazolam], Opioids [Fentanyl, Morphine], anesthetic agent [propofol], and neuromuscular blocking agents to achieve better ventilation goal in patients with severe ARDS, b) prolonged ICU stay, c) presence of cardiogenic and septic shock, d) CNS side effects of other medications including corticosteroid, antibiotics etc.6,9-11
Finally, cerebrovascular injury is being commonly reported in patients with COVID-19. Studies have shown that patients with severe COVID-19 had higher cardio-cerebrovascular comorbidities including older age, hypertension, diabetes mellitus, hyperlipidemia, heart failure, coronary artery disease, and cerebrovascular disease. A recent study also showed that patients with severe COVID-19 had higher cerebrovascular events as compared to patients without severe illness. We agree with the authors that future studies will be instrumental in clarifying patterns, predictors and outcome of COVID-19 related neurological injury.

Reference:


